Global Biopharma buffer Market Size, Share, and Trends Analysis Report, By Type (Phosphates Type, Acetates Type, TRIS Type, and Others) and By Application (Research Institution, Pharmaceutical Industry, and Others) Forecast (2022-2028)

The global biopharma buffer market is anticipated to grow at a significant CAGR of 7.3% during the forecast period (2022-2028). The global biopharma buffer market is growing due to the increasing demand for vaccines, blood components, allergenic, gene therapies, tissues, recombinant therapeutic protein, blood plasma, and living cells used in cell therapy globally. The market is also growing due to the increasing pharmaceutical activities and laboratory experiments for the development of the medical industry. Additionally, the rise in effective therapeutic drugs, the emergence of new manufacturers, and the adoption of new drugs for the treatment of chronic diseases are also driving the growth of the market. The ongoing COVID-19 pandemic has positively impacted the global biopharma buffer market. The increased demand for pandemic-related biopharma development and manufacturing of vaccines and drugs had propelled the growth of the global biopharma buffer market.

 

 

The market player is also contributing significantly to the growth of the market by the adoption of various strategies including mergers and acquisitions, geographical expansion, partnerships, collaborations, and launches, to stay competitive in the market. For instance-

 

 

• In October 2021, Aceto acquired A&C BIO BUFFER LTD. which manufactures more than 50 products, including biological buffers, process solutions, cleaning solutions, and distilled water for injection.
• In June 2021, Lonza partnered with Moderna, Inc. for launching RNA (mRNA) therapeutics and vaccines, to manufacture the drug substance for the COVID-19 vaccine.
• in December 2020, Aurinia Pharmaceuticals Inc. collaborated with Lonza to build a dedicated manufacturing capacity within Lonza’s existing small molecule API facility in Visp, Switzerland which will be equipped with state-of-the-art manufacturing equipment to provide cost and production efficiency for the manufacture of voclosporin, while expanding existing capacity and providing supply security to meet future commercial demand.

 

Market Coverage

• The market number available for – 2022-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Type
  • By Application
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape– Merck & Co., Inc., Bio-Rad Laboratories, Inc., BD, General Electric Co., and Hamilton Co., among others.

 

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

 

Global Biopharma Buffer Market Report by Segment

By Type

• Phosphates Type
• Acetates Type
• TRIS Type
• Others

By Application

• Research Institution
• Pharmaceutical Industry
• Others

 

Global Biopharma Buffer Market Report by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa